BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15689452)

  • 1. Classification of BRCA1 missense variants of unknown clinical significance.
    Phelan CM; Dapic V; Tice B; Favis R; Kwan E; Barany F; Manoukian S; Radice P; van der Luijt RB; van Nesselrooij BP; Chenevix-Trench G; kConFab ; Caldes T; de la Hoya M; Lindquist S; Tavtigian SV; Goldgar D; Borg A; Narod SA; Monteiro AN
    J Med Genet; 2005 Feb; 42(2):138-46. PubMed ID: 15689452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
    Mirkovic N; Marti-Renom MA; Weber BL; Sali A; Monteiro AN
    Cancer Res; 2004 Jun; 64(11):3790-7. PubMed ID: 15172985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
    Vallon-Christersson J; Cayanan C; Haraldsson K; Loman N; Bergthorsson JT; Brøndum-Nielsen K; Gerdes AM; Møller P; Kristoffersson U; Olsson H; Borg A; Monteiro AN
    Hum Mol Genet; 2001 Feb; 10(4):353-60. PubMed ID: 11157798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
    Ostrow KL; McGuire V; Whittemore AS; DiCioccio RA
    Cancer Genet Cytogenet; 2004 Sep; 153(2):177-80. PubMed ID: 15350310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
    Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
    Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
    Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
    Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
    Carvalho M; Pino MA; Karchin R; Beddor J; Godinho-Netto M; Mesquita RD; Rodarte RS; Vaz DC; Monteiro VA; Manoukian S; Colombo M; Ripamonti CB; Rosenquist R; Suthers G; Borg A; Radice P; Grist SA; Monteiro AN; Billack B
    Mutat Res; 2009 Jan; 660(1-2):1-11. PubMed ID: 18992264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
    Abkevich V; Zharkikh A; Deffenbaugh AM; Frank D; Chen Y; Shattuck D; Skolnick MH; Gutin A; Tavtigian SV
    J Med Genet; 2004 Jul; 41(7):492-507. PubMed ID: 15235020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
    Tavtigian SV; Deffenbaugh AM; Yin L; Judkins T; Scholl T; Samollow PB; de Silva D; Zharkikh A; Thomas A
    J Med Genet; 2006 Apr; 43(4):295-305. PubMed ID: 16014699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
    Langerud J; Jarhelle E; Van Ghelue M; Ariansen SL; Iversen N
    Hum Genomics; 2018 Nov; 12(1):51. PubMed ID: 30458859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.
    Rostagno P; Gioanni J; Garino E; Vallino P; Namer M; Frenay M
    J Hum Genet; 2003; 48(7):362-6. PubMed ID: 12827452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
    Lovelock PK; Healey S; Au W; Sum EY; Tesoriero A; Wong EM; Hinson S; Brinkworth R; Bekessy A; Diez O; Izatt L; Solomon E; Jenkins M; Renard H; Hopper J; Waring P; Tavtigian SV; Goldgar D; Lindeman GJ; Visvader JE; Couch FJ; Henderson BR; Southey M; Chenevix-Trench G; Spurdle AB; Brown MA;
    J Med Genet; 2006 Jan; 43(1):74-83. PubMed ID: 15923272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
    Carvalho MA; Marsillac SM; Karchin R; Manoukian S; Grist S; Swaby RF; Urmenyi TP; Rondinelli E; Silva R; Gayol L; Baumbach L; Sutphen R; Pickard-Brzosowicz JL; Nathanson KL; Sali A; Goldgar D; Couch FJ; Radice P; Monteiro AN
    Cancer Res; 2007 Feb; 67(4):1494-501. PubMed ID: 17308087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
    Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
    Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of common BRCA1 and BRCA2 variants.
    Deffenbaugh AM; Frank TS; Hoffman M; Cannon-Albright L; Neuhausen SL
    Genet Test; 2002; 6(2):119-21. PubMed ID: 12215251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.
    Shattuck-Eidens D; Oliphant A; McClure M; McBride C; Gupte J; Rubano T; Pruss D; Tavtigian SV; Teng DH; Adey N; Staebell M; Gumpper K; Lundstrom R; Hulick M; Kelly M; Holmen J; Lingenfelter B; Manley S; Fujimura F; Luce M; Ward B; Cannon-Albright L; Steele L; Offit K; Thomas A
    JAMA; 1997 Oct; 278(15):1242-50. PubMed ID: 9333265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
    Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
    Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
    Osorio A; Milne RL; Honrado E; Barroso A; Diez O; Salazar R; de la Hoya M; Vega A; Benítez J
    Hum Mutat; 2007 May; 28(5):477-85. PubMed ID: 17279547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.